Kenvue Inc.

Equities

KVUE

US49177J1025

Personal Products

Real-time Estimate Cboe BZX 10:55:15 2024-12-13 am EST 5-day change 1st Jan Change
22.16 USD -0.74% Intraday chart for Kenvue Inc. -3.00% +2.90%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Barclays Initiates Kenvue at Equalweight With $23 Price Target Dec. 12 MT
Deutsche Bank Downgrades Kenvue to Hold From Buy, Adjusts Price Target to $24 From $25 Dec. 12 MT
HSBC Adjusts Price Target on Kenvue to $23 From $21, Keeps Hold Rating Dec. 11 MT
RBC Upgrades Kenvue to Outperform From Sector Perform, Price Target is $24 Dec. 09 MT
Kenvue Inc. Presents at Morgan Stanley Global Consumer & Retail Conference, Dec-04-2024 11:45 AM Dec. 04
BNP Paribas Exane Lifts Price Target on Kenvue to $24 From $22 Nov. 20 MT
Tranche Update on Kenvue Inc.'s Equity Buyback Plan announced on October 26, 2023. Nov. 07 CI
Kenvue Inc., Q3 2024 Earnings Call, Nov 07, 2024 Nov. 07
Stock Futures Rise Amid Trump Victory as Traders Focus on Fed Decision; Asia, Europe Rise Nov. 07 MT
Kenvue's Q3 Adjusted Earnings, Net Sales Decline Nov. 07 MT
Earnings Flash (KVUE) KENVUE Posts Q3 EPS $0.28 Nov. 07 MT
Earnings Flash (KVUE) KENVUE Posts Q3 Revenue $3.90B Nov. 07 MT
Kenvue misses quarterly sales estimates on sluggish skincare sales Nov. 07 RE
Kenvue Inc. Provides Earnings Guidance for the Year 2024 Nov. 07 CI
Kenvue Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 07 CI
Kenvue Likely to See 'Muted' Q3 Amid Skin Health & Beauty Challenges, RBC Says Nov. 05 MT
Kenvue Canada Inc., a Division of Kenvue Inc., Expands Ontario Manufacturing Facility to Boost Production of Over-The-Counter Medicines Nov. 04 CI
Starboard Value Reportedly Buys Stake in Kenvue Oct. 23 MT
Starboard says Kenvue's skin health segment is weighing on performance Oct. 22 RE
Dow, S&P 500 Retreat From Record Highs Ahead of Major Earnings Oct. 21 MT
Dow, S&P 500 Retreat From Record Highs Ahead of Week's Major Earnings Oct. 21 MT
Equities Mostly Fall Intraday as Markets Await This Week's Major Earnings Oct. 21 MT
Sector Update: Consumer Stocks Mixed Pre-Bell Monday Oct. 21 MT
Sector Update: Consumer Oct. 21 MT
Starboard Value Reportedly Buys Stake in Kenvue Oct. 21 MT
Chart Kenvue Inc.
KVUE: Dynamic Chart
Logo Kenvue Inc.
Kenvue Inc. is one of the world leaders in the design, manufacture and marketing of consumer healthcare products. The group offers products for health, beauty, baby care, oral care, skin care and more. Net sales break down by family of products as follows: - self care products (41,8%): for the treatment of coughs, colds, allergies, pain, indigestion, constipation, etc. (brands Zyrtec, Benadryl, Zarbee's, Frenadol, Codral, Reactine, Tylenol, Motrin, Calpol, Nicorette, Imodium, Pepcid, Microlax, Daktarin, etc.); - personal care products (29.9%): primarily oral care, baby care, women's health and wound care products (Listerine, Desitin, Carefree, Stayfree, Band-Aid, Neosporin brands, etc.); - beauty and skin care products (28.3%): hair care products, sun protection products, face and body care products, etc. (Neutrogena, Aveeno, Clean&Clear, Lubriderm, Johnsons, Neostrata, OGX, Rogaine brands, etc.). Product marketing is assured through direct sales, distributors and the Internet. Net sales are distributed geographically as follows: North America (49.3%), Europe-Middle East-Africa (21.9%), Asia-Pacific (20.1%) and Latin America (8.7%).
Employees
22,000
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
surperformance-ratings-light-chart KENVUE-INCMore Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
22.32USD
Average target price
24.64USD
Spread / Average Target
+10.38%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. KVUE Stock
  4. News Kenvue Inc.
  5. Earnings Flash (KVUE) KENVUE Posts Q3 Revenue $3.90B